» Articles » PMID: 28332094

Cryptic Exon Incorporation Occurs in Alzheimer's Brain Lacking TDP-43 Inclusion but Exhibiting Nuclear Clearance of TDP-43

Overview
Specialty Neurology
Date 2017 Mar 24
PMID 28332094
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Abnormal accumulation of TDP-43 into cytoplasmic or nuclear inclusions with accompanying nuclear clearance, a common pathology initially identified in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), has also been found in Alzheimer' disease (AD). TDP-43 serves as a splicing repressor of nonconserved cryptic exons and that such function is compromised in brains of ALS and FTD patients, suggesting that nuclear clearance of TDP-43 underlies its inability to repress cryptic exons. However, whether TDP-43 cytoplasmic aggregates are a prerequisite for the incorporation of cryptic exons is not known. Here, we assessed hippocampal tissues from 34 human postmortem brains including cases with confirmed diagnosis of AD neuropathologic changes along with age-matched controls. We found that cryptic exon incorporation occurred in all AD cases exhibiting TDP-43 pathology. Furthermore, incorporation of cryptic exons was observed in the hippocampus when TDP-43 inclusions was restricted only to the amygdala, the earliest stage of TDP-43 progression. Importantly, cryptic exon incorporation could be detected in AD brains lacking TDP-43 inclusion but exhibiting nuclear clearance of TDP-43. These data supports the notion that the functional consequence of nuclear depletion of TDP-43 as determined by cryptic exon incorporation likely occurs as an early event of TDP-43 proteinopathy and may have greater contribution to the pathogenesis of AD than currently appreciated. Early detection and effective repression of cryptic exons in AD patients may offer important diagnostic and therapeutic implications for this devastating illness of the elderly.

Citing Articles

RNA dysregulation in neurodegenerative diseases.

Li Y, Sun S EMBO J. 2025; 44(3):613-638.

PMID: 39789319 PMC: 11790913. DOI: 10.1038/s44318-024-00352-6.


Abnormal Splicing Events due to Loss of Nuclear Function of TDP-43: Pathophysiology and Perspectives.

Koike Y JMA J. 2024; 7(3):313-318.

PMID: 39114608 PMC: 11301021. DOI: 10.31662/jmaj.2024-0038.


CUTS RNA Biosensor for the Real-Time Detection of TDP-43 Loss-of-Function.

Xie L, Merjane J, Bergmann C, Xu J, Hurtle B, Donnelly C bioRxiv. 2024; .

PMID: 39026766 PMC: 11257528. DOI: 10.1101/2024.07.12.603231.


Depletion of TDP-43 exacerbates tauopathy-dependent brain atrophy by sensitizing vulnerable neurons to caspase 3-mediated endoproteolysis of tau in a mouse model of Multiple Etiology Dementia.

Baghel M, Burns G, Tsapatsis M, Peethambaran Mallika A, Cruz A, Cao T bioRxiv. 2024; .

PMID: 38979270 PMC: 11230425. DOI: 10.1101/2024.06.26.600814.


Frontotemporal lobar degeneration targets brain regions linked to expression of recently evolved genes.

Pasquini L, Pereira F, Seddighi S, Zeng Y, Wei Y, Illan-Gala I Brain. 2024; 147(9):3032-3047.

PMID: 38940350 PMC: 11370792. DOI: 10.1093/brain/awae205.


References
1.
Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K . Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006; 112(4):389-404. PMC: 3906709. DOI: 10.1007/s00401-006-0127-z. View

2.
Cohen T, Lee V, Trojanowski J . TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. Trends Mol Med. 2011; 17(11):659-67. PMC: 3202652. DOI: 10.1016/j.molmed.2011.06.004. View

3.
Amador-Ortiz C, Dickson D . Neuropathology of hippocampal sclerosis. Handb Clin Neurol. 2008; 89:569-72. DOI: 10.1016/S0072-9752(07)01253-5. View

4.
Amador-Ortiz C, Lin W, Ahmed Z, Personett D, Davies P, Duara R . TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol. 2007; 61(5):435-45. PMC: 2677204. DOI: 10.1002/ana.21154. View

5.
Josephs K, Murray M, Whitwell J, Tosakulwong N, Weigand S, Petrucelli L . Updated TDP-43 in Alzheimer's disease staging scheme. Acta Neuropathol. 2016; 131(4):571-85. PMC: 5946692. DOI: 10.1007/s00401-016-1537-1. View